title: [Results of treating patients with mycobacterial respiratory infections negative for HIV virus (retrospective study)].
abstract: In this study the results of treatment of 37 patients with non-tuberculous mycobacterial disease were analyzed. The responsible strains were indentified as M. kansasi in 16 patients, M. avium-intracellulare in 10 patients, M. avium intracellulare and M. xenopi in 3 patients, M. xenopi and M. chalone in 7 patients. Patients with M. kansasi infection had been treated for 12 months. Sputum culture became negative in all patients after 2 months of treatment mainly with ryfamipcin (R) and etambutol (E). Thirteen patients infected with M. avium-intracellulare or M. avium-intracellulare and M. xenopi had been treated for 24 months according to the drug sensitivity tests. Sputum conversion was achieved only in 4 out of 11 patients. In 3 patients sputum examination was positive inspite for the regression of chest X-ray lesions. In 2 cases despite the resistance in vitro to all drugs, during treatment with H, R, E and aminoglicoside-sputum culture become negative. Four patients died due to the progression of non-tuberculous mycobacterial infection. In a group of 7 patients infected with M. xenopi sputum--negative results were observed after 2 months of treatment. One patient infected with M. chaelone had been treated for 6 months with clarithromycine, and sputum culture become negative after 2 months of the treatment.
authors.affiliation: Przychodni Przyklinicznej, Warszawa.
authors.forename: S
authors.initials: S
authors.lastname: Aleksandra
authors.forename: Z
authors.initials: Z
authors.lastname: Jacek
authors.forename: R
authors.initials: R
authors.lastname: Paweł
authors.forename: A K
authors.initials: AK
authors.lastname: Ewa
authors.forename: K
authors.initials: K
authors.lastname: Magdalena
mesh_terms: D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000008:administration & dosage; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D018023:HIV Seronegativity; D006801:Humans; D008297:Male; D008875:Middle Aged; D009161:Mycobacterium / Q000302:isolation & purification; D009164:Mycobacterium Infections / Q000188:drug therapy* / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000995:Antitubercular Agents; D004977:Ethambutol; D012293:Rifampin